Skip to main content

Table 1 General characteristics of the three cohorts: patients with MD, patients with RA, and healthy control participants.

From: Triglyceride-independent associations between circulating levels of apolipoprotein C-III and biomarkers of inflammation

 

Metabolic disorders (n = 906)

Rheumatoid Arthritis (n = 192)

Controls (n = 144)

P - value

Age (years, IQR)

60 (50–68) #, ×

57 (49–65) †

47 (40–55)

< 0.001

Sex (women, %)

472, 52% #,×

125, 65%

102, 71%

< 0.001

BMI (kg/m2, IQR)

30.7 (28.0–34.0) #, ×

26.6 (23.2–30.6) †

23.6 (21.8–25.5)

< 0.001

Hypertension (yes, %)

599, 66% #, ×

103, 54% †

0, 0%

0.003

T2DM (yes, %)

622, 69% #,×

0, 0%

0, 0%

< 0.001

Total cholesterol (mg/dL, IQR)

203.4 (177.9–233.6) ×

201.0 (182.0–226.0)

194.1 (170.9–220.0)

0.02

LDL-C (mg/dL, IQR)

114.9 (92.8–137.7)

114.0 (99.0–134.2)

109.5 (88.3–132.0)

0.07

ApoB (mg/dL, IQR)

94.5 (83.9–108.6) ×

94 (83–111) †

89.9 (76.8–105.3)

0.001

HDL-C (mg/dL, IQR)

41.4 (28.7–51.8) #,×

66 (54–76.2) †

60.5 (48.6–73.3)

< 0.001

TG (mg/dL, IQR)

139.1 (99.2–203.3) #, ×

89.5 (66.7–119) †

69.5 (52.26–89.3)

< 0.001

Glucose 88.5 (82–97)

112 (97.7–139) #, ×

88.5 (82–97)

88 (83–94)

< 0.001

ApoCIII (mg/dL, IQR)

10.5 (8.2–14.0) #, ×

8.2 (5.8–10.9)

7.6 (5.8–10.4)

< 0.001

CRP (mg/L, IQR)

2.5 (1.3–4.3) #, ×

4.5 (2–9.3) †

0.9 (0.5–1.6)

< 0.001

Glyc-A (µmol/L)

783.5 (674.3–923) #, ×

642.7 (575.6–734.4) †

578.9 (513.2–633.6)

< 0.001

Glyc-B (µmol/L)

294.5 (246.4–349.3) #,×

325.2 (297.1–363.2) †

272.9 (243.9–301.7)

< 0.001

Glyc-F (µmol/L)

284.1 (244.6–331.2) #, ×

184.3 (167–204.6)

186.8 (164.9–227.1)

< 0.001

Lipid-lowering medication (yes, %)

269, 30% #, ×

27, 14% †

6, 4%

< 0.001

Hypotensive medication (yes, %)

410, 45.2% #, ×

56, 29% †

1, 0.7%

< 0.001

Glucose-lowering therapies(yes, %)

263, 29% #, ×

0, 0%

2, 1%

< 0.001

RA medication (yes, %)

0, 0% #

187, 97% †

0, 0%

< 0.001

  1. Differences across the three groups were evaluated using the Kruskal-Wallis test. Post-hoc pairwise comparisons were conducted using the Wilcoxon rank sum test, with p-values adjusted using the Holm method. The following symbols denote significant differences (p < 0.05): #: Between patients with MD and those with RA. ×: Between patients with MD and healthy control participants. †: Between patients with RA and healthy control participants. BMI, body mass index; T2DM, type 2 diabetes mellitus; ApoB, apolipoprotein B; TG, triglycerides; hsCRP, high-sensitivity C-reactive protein; Glyc-A, glycoprotein A; Glyc-B, glycoprotein B; Glyc-F, glycoprotein F.
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840